Peptide Research Glossary
A comprehensive A–Z reference of peptide and research compound terminology. Covering synthesis, testing, pharmacology, and laboratory practice.
A
5 termsADME
Absorption Distribution Metabolism and Excretion. The four pharmacokinetic parameters studied in in vivo research models to characterise compound behaviour in biological systems. ADME profiling is a standard component of preclinical pharmacokinetic research and encompasses the full lifecycle of a compound from initial absorption through to elimination.
Agonist
A compound that binds to a receptor and activates it, initiating a downstream signalling cascade. In peptide research, agonists are used to investigate receptor function and characterise intracellular signalling pathways. Full agonists produce maximal receptor activation, while partial agonists elicit submaximal responses at full receptor occupancy. The degree of agonist activity is typically quantified using EC50 values in dose-response assays.
Amino Acid
The fundamental monomeric unit from which peptides and proteins are constructed. Each amino acid consists of a central carbon atom bonded to an amino group, a carboxyl group, a hydrogen atom and a variable side chain (R group) that determines its chemical properties. Twenty standard L-amino acids are encoded by the genetic code, though non-standard residues such as D-amino acids and synthetic analogues are frequently incorporated into research peptides to modify biological activity or metabolic stability.
Analogue
A synthetic compound structurally related to a naturally occurring molecule but incorporating deliberate modifications to one or more chemical features. In peptide research, analogues are designed through amino acid substitutions, terminus modifications, backbone alterations or conjugation strategies to investigate structure-activity relationships. Analogues serve as essential tools for studying how specific structural changes influence receptor binding, signalling and pharmacokinetic parameters.
Antagonist
A compound that binds to a receptor without activating it and blocks the binding of endogenous or exogenous agonists. Antagonists are used in preclinical research to characterise receptor function by observing the consequences of pathway inhibition. Competitive antagonists bind reversibly to the orthosteric site, while non-competitive antagonists bind allosteric sites or irreversibly to block receptor activation regardless of agonist concentration.
B
4 termsBacteriostatic Water
Sterile water containing 0.9% benzyl alcohol as a bacteriostatic preservative. One of several solvents used in laboratory reconstitution of lyophilised compounds; other commonly used solvents include sterile water for injection, phosphate-buffered saline (PBS), and dilute acetic acid, the choice depending on compound solubility and assay requirements. The benzyl alcohol inhibits microbial growth following initial vial puncture, permitting multi-use access from a single container. Intended for in vitro research use only.
Binding Affinity
A quantitative measure of the strength of interaction between a ligand and its target receptor, typically expressed as a dissociation constant (Kd). Lower Kd values indicate stronger binding. Binding affinity is determined using in vitro assays such as radioligand displacement, surface plasmon resonance or isothermal titration calorimetry. It is a fundamental parameter in receptor pharmacology research and a key variable in structure-activity relationship studies.
Bioavailability
The fraction of an administered compound that reaches systemic circulation in an unmetabolised form. Bioavailability is a key pharmacokinetic parameter characterised in in vivo preclinical research models and is influenced by absorption route, first-pass metabolism, enzymatic degradation and formulation. Peptide compounds typically present bioavailability challenges due to proteolytic susceptibility, which has driven research into structural modifications such as D-amino acid substitution, PEGylation and terminus modification.
Blood-Brain Barrier (BBB)
The selective semipermeable membrane separating circulating blood from the central nervous system extracellular fluid. Formed by tight junctions between brain endothelial cells, the BBB restricts the passage of most circulating molecules into the CNS. BBB penetration is a key pharmacokinetic variable studied in preclinical peptide research, and strategies to facilitate CNS access including lipidation, cell-penetrating peptide conjugation and receptor-mediated transcytosis are active areas of investigation.
C
2 termsCAS Number
Chemical Abstracts Service registry number. A unique numerical identifier assigned to every chemical substance described in the open scientific literature. CAS numbers provide an unambiguous reference for compound identification, independent of naming conventions or synonyms. In peptide research, CAS numbers are used to confirm compound identity across suppliers, publications and regulatory documentation.
Certificate of Analysis
A quality assurance document issued for a specific production batch of a research compound. A Certificate of Analysis (COA) typically reports compound identity confirmation, purity percentage, analytical method (such as HPLC or mass spectrometry), batch number and any relevant impurity data. COAs provide the documentation required for reproducible experimental work and are available on request for all compounds.
D
3 termsD-Amino Acid
A mirror-image stereoisomeric form of the standard L-amino acid configuration. Incorporation of D-amino acids into synthetic peptides confers resistance to proteolytic degradation by endogenous enzymes, which preferentially recognise L-configured substrates. D-amino acid substitution is a widely used structural modification strategy in preclinical peptide research. An example is the D-Ala residue at position 2 in Dermorphin, which has been observed to contribute to the compound's enzymatic stability and receptor selectivity profile.
Disulfide Bond
A covalent bond formed between the sulfur atoms of two cysteine residues within a peptide or protein. Disulfide bonds stabilise three-dimensional structure and are critical to the biological activity of many research peptides including oxytocin (Cys1-Cys6 intramolecular bond) and insulin-like growth factors (intermolecular bonds). Disulfide bond formation and reduction are studied in vitro to understand folding, stability and structure-function relationships.
Dose-Response Relationship
The quantitative relationship between the concentration of a compound administered in a research model and the magnitude of the observed biological response. Dose-response curves are fundamental to in vitro and in vivo pharmacology research and are used to determine parameters such as EC50, maximal response (Emax) and Hill coefficient. These relationships are essential for comparing compound potency and characterising receptor pharmacology.
E
4 termsEC50
The half-maximal effective concentration. The concentration of a compound that produces 50 percent of the maximal observed response in a defined assay system. EC50 is a standard measure of compound potency in in vitro pharmacology research and is determined from dose-response curve analysis. Lower EC50 values indicate greater potency. EC50 values are assay-dependent and should be interpreted within the specific experimental context in which they were measured.
Endogenous
Originating from within a biological system. In peptide research, endogenous refers to compounds that are naturally produced by the organism under study, such as growth hormone-releasing hormone, oxytocin or insulin-like growth factor-1. Endogenous peptides serve as reference compounds against which synthetic analogues are compared in structure-activity relationship and receptor pharmacology studies.
Enzymatic Degradation
The breakdown of a peptide by proteolytic enzymes present in biological systems. Enzymatic degradation is a primary pharmacokinetic challenge investigated in peptide research, as most linear peptides are rapidly cleaved by endopeptidases, aminopeptidases and carboxypeptidases in serum and tissue homogenates. This degradation directly informs structural modification strategies such as D-amino acid substitution, terminus modification, cyclisation and PEGylation, all of which are designed to extend compound stability in preclinical research models.
Exogenous
Originating from outside a biological system. In peptide research, exogenous refers to compounds that are synthetically produced and administered to a research model, as distinct from the endogenous peptides naturally present in the system. Exogenous administration of synthetic peptides or analogues is a standard approach in preclinical pharmacology for investigating receptor function and downstream signalling pathways.
G
2 termsGHRH
Growth Hormone-Releasing Hormone. A 44-amino acid hypothalamic neuropeptide that acts at the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells. GHRH is the endogenous ligand for GHRHR, a Class B G protein-coupled receptor that signals through Gs-coupled adenylyl cyclase and cAMP accumulation. Synthetic GHRH analogues such as Sermorelin (GRF 1-29), CJC-1295 and Tesamorelin have been developed as research tools incorporating structural modifications investigated for their influence on receptor binding and metabolic stability.
Growth Hormone Secretagogue
A class of synthetic compounds that act at the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor, to activate downstream signalling cascades associated with growth hormone release in preclinical research models. GHS-R1a is a Gq-coupled GPCR. Secretagogues include synthetic hexapeptides such as GHRP-2, GHRP-6, Hexarelin and Ipamorelin, each of which has been studied for its distinct receptor binding characteristics and structure-activity profile.
H
2 termsHalf-Life
The time required for the concentration of a compound in a defined biological compartment to decrease to 50 percent of its initial value. Half-life is a fundamental pharmacokinetic parameter measured in in vivo preclinical research models and is influenced by enzymatic degradation, renal clearance, protein binding and volume of distribution. Peptide half-life is a primary driver of structural modification research, as most unmodified linear peptides exhibit short circulating half-lives due to rapid proteolysis.
HPLC
High-Performance Liquid Chromatography. An analytical technique used to separate, identify and quantify individual components within a mixture. In peptide research, HPLC is a standard method for assessing compound purity by separating the target peptide from synthesis by-products, truncated sequences and other impurities. Reverse-phase HPLC (RP-HPLC) is the most common mode used for peptide analysis. HPLC data is a core component of Certificates of Analysis.
I
4 termsIGF-1
Insulin-like Growth Factor 1. A 70-amino acid polypeptide that signals through the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase that activates PI3K/Akt and MAPK/ERK signalling cascades. IGF-1 activity in biological systems is modulated by a family of six IGF-binding proteins (IGFBP-1 through IGFBP-6) that sequester the ligand and regulate its bioavailability. Structural analogues such as IGF-1 LR3 and Des(1-3)IGF-1 have been developed as research tools with altered IGFBP binding profiles to facilitate investigation of receptor-level signalling.
In Vitro
Latin for 'in glass'. Refers to experiments conducted outside a living organism, typically in cell cultures, tissue preparations, isolated organ systems or biochemical assay systems. In vitro studies are a foundational component of preclinical peptide research, enabling controlled investigation of receptor binding, intracellular signalling and compound stability under defined conditions.
In Vivo
Latin for 'in the living'. Refers to experiments conducted within a living organism, typically rodent or other animal research models. In vivo preclinical studies investigate pharmacokinetic parameters, biodistribution, compound stability and systemic pathway engagement under physiological conditions that cannot be replicated in cell-based systems. In vivo data complements in vitro findings and provides context for compound behaviour in complex biological environments.
Intramuscular (IM)
A route of compound administration into skeletal muscle tissue, studied as a pharmacokinetic research variable in preclinical in vivo models. Intramuscular administration is investigated for its influence on absorption kinetics, depot formation and bioavailability relative to other administration routes. The rate of absorption from an intramuscular depot site is influenced by local blood flow, compound molecular weight and formulation characteristics. IM pharmacokinetics are characterised in rodent and other preclinical research models.
K
1 termsKd
Dissociation constant. A quantitative measure of the equilibrium between bound and unbound states of a ligand-receptor complex. Kd is expressed in molar concentration units and represents the ligand concentration at which 50 percent of available receptor binding sites are occupied at equilibrium. Lower Kd values indicate higher binding affinity. Kd is determined through in vitro binding assays such as saturation binding, competition binding or surface plasmon resonance.
L
3 termsLigand
Any molecule that binds to a specific site on a target receptor or protein. In peptide research, ligands include endogenous peptides, synthetic agonists, antagonists and allosteric modulators. The term encompasses any compound that forms a defined interaction with a biological target, regardless of whether that interaction produces receptor activation. Ligand-receptor interactions are characterised by binding affinity (Kd) and functional potency (EC50).
Lyophilisation
Also known as freeze-drying. A dehydration process used to preserve peptide research compounds by removing water under vacuum at low temperature. Lyophilisation converts a peptide solution into a dry powder (lyophilised powder) that maintains chemical stability during storage and transport. The resulting lyophilised cake or powder is reconstituted with an appropriate solvent before use in experimental protocols. Lyophilisation is the standard preservation method for synthetic peptide research compounds.
Lyophilised Storage Conditions
The recommended storage parameters for lyophilised peptide compounds in research settings. Lyophilised peptides are typically stored at minus 20 degrees Celsius protected from light and moisture to maintain chemical integrity and purity over time. Desiccant should be included in storage containers where possible. Reconstitution should be performed immediately before use in experimental protocols, and reconstituted solutions should be stored according to compound-specific stability data.
M
4 termsMass Spectrometry
An analytical technique that measures the mass-to-charge ratio of ions to determine the molecular weight and structural identity of a compound. In peptide research, mass spectrometry (MS) is used alongside HPLC to confirm compound identity, detect impurities and verify sequence accuracy. Common ionisation methods for peptide analysis include electrospray ionisation (ESI) and matrix-assisted laser desorption ionisation (MALDI). MS data forms part of the analytical package reported in Certificates of Analysis.
Melanocortin Receptor
A family of five G protein-coupled receptors (MC1R through MC5R) that bind melanocortin peptides derived from proopiomelanocortin (POMC). Each receptor subtype has a distinct tissue distribution and signalling profile. MC1R is expressed in melanocytes, MC2R is the ACTH receptor on adrenocortical cells, MC3R and MC4R are expressed in the central nervous system, and MC5R is found in exocrine glands. Melanocortin receptors signal primarily through Gs-coupled adenylyl cyclase activation. Synthetic melanocortin agonists and antagonists are used to investigate subtype-specific receptor pharmacology.
Molecular Formula
The notation describing the exact number and type of atoms present in a single molecule of a compound. For peptides, the molecular formula reflects the amino acid composition after peptide bond formation and any post-synthetic modifications. Molecular formulae are used alongside molecular weight and CAS number as standard identifiers for compound characterisation in research documentation.
Molecular Weight
The sum of the atomic weights of all atoms in a molecule, expressed in grams per mole (g/mol) or Daltons (Da). Molecular weight is a fundamental physical property used to characterise peptide research compounds and is determined analytically by mass spectrometry. It is used in concentration calculations, stoichiometric analysis and as a reference parameter in compound identification.
N
1 termsN-terminus / C-terminus
The two ends of a linear peptide chain. The N-terminus (amino terminus) bears a free amino group and corresponds to the first residue in the sequence. The C-terminus (carboxyl terminus) bears a free carboxyl group and corresponds to the last residue. By convention, peptide sequences are written from N-terminus to C-terminus. Both termini are common sites for chemical modification strategies including acetylation, amidation, PEGylation and lipidation, which are investigated for their influence on compound stability and biological activity.
P
7 termsPEGylation
The covalent attachment of polyethylene glycol (PEG) polymer chains to a peptide or protein. PEGylation is a structural modification strategy investigated in preclinical research for its influence on pharmacokinetic parameters including enzymatic stability, circulating half-life and immunogenicity. The PEG moiety increases hydrodynamic radius and shields the peptide from proteolytic degradation. PEG chain length and attachment site are key variables in PEGylation research. An example is PEG-MGF, the PEGylated form of Mechano Growth Factor.
Peptide
A short chain of amino acids linked by peptide bonds, typically comprising 2 to 50 residues. Peptides are distinguished from proteins primarily by chain length, though the boundary is not rigidly defined. In research contexts, synthetic peptides are produced via solid-phase peptide synthesis and are used as tools to investigate receptor pharmacology, signal transduction pathways and structure-activity relationships. Peptides may be linear or cyclic and can incorporate non-standard amino acids and chemical modifications.
Peptide Bond
The covalent amide bond formed between the carboxyl group of one amino acid and the amino group of the next through a condensation reaction that releases water. Peptide bonds form the backbone of all peptide and protein structures. The bond has partial double-bond character, restricting rotation and conferring planarity to the amide linkage. Peptide bonds are the primary targets of proteolytic enzymes in biological systems.
Peptide Bond Hydrolysis
The cleavage of a peptide bond by water, typically catalysed by proteolytic enzymes (proteases and peptidases) in biological systems. Peptide bond hydrolysis is the primary mechanism of peptide degradation and a fundamental process studied in preclinical pharmacokinetic research. Understanding the sites and rates of hydrolysis in biological matrices directly informs structural modification strategies — including D-amino acid substitution, backbone methylation and cyclisation — designed to confer proteolytic resistance.
Pharmacokinetics
The study of how a compound moves through a biological system, encompassing absorption, distribution, metabolism and excretion (ADME). Pharmacokinetic parameters — including bioavailability, half-life, volume of distribution and clearance — are characterised in in vivo preclinical research models. For peptide compounds, pharmacokinetic research is particularly focused on proteolytic stability, routes of absorption and strategies to extend systemic exposure.
Pulsatile Release
A pattern of intermittent, episodic secretion observed in preclinical research models for certain endogenous hormones and neuropeptides. Growth hormone, for example, is released from pituitary somatotroph cells in discrete pulses rather than continuously. Pulsatile release kinetics are a significant research variable in secretagogue pharmacology, as the temporal pattern of receptor activation has been observed to influence downstream signalling responses differently from sustained activation. Preclinical study designs frequently incorporate pulsatile dosing protocols to model physiological secretion patterns.
Purity
The proportion of a compound sample that consists of the intended target molecule, expressed as a percentage. Purity is determined by analytical methods such as HPLC and mass spectrometry and is reported on the Certificate of Analysis. Research-grade peptide compounds are typically supplied at 98 percent purity or above. Impurities may include truncated sequences, deletion sequences, oxidised variants and residual solvents from the synthesis process.
R
3 termsReceptor
A protein, typically located on the cell surface or within the cell, that binds a specific ligand and initiates a biological response through signal transduction. Receptors are classified by structure and signalling mechanism into families including G protein-coupled receptors (GPCRs), receptor tyrosine kinases (RTKs), ligand-gated ion channels and nuclear receptors. In peptide research, receptor pharmacology is investigated through binding assays, functional signalling assays and structure-activity relationship studies.
Receptor Selectivity
The degree to which a compound preferentially binds one receptor subtype over others within a receptor family. Receptor selectivity is a central criterion in structure-activity relationship research and a key variable in comparative pharmacology studies. Selectivity is quantified by comparing binding affinities (Kd values) or functional potencies (EC50 values) across receptor subtypes. Highly selective compounds are valuable research tools for attributing biological observations to specific receptor-mediated pathways.
Reconstitution
The process of dissolving a lyophilised (freeze-dried) peptide compound in an appropriate solvent to produce a solution for use in experimental protocols. Common reconstitution solvents include bacteriostatic water, sterile water and dilute acetic acid. The choice of solvent depends on the peptide's solubility characteristics, isoelectric point and intended assay conditions. Reconstituted peptide solutions should be handled according to compound-specific stability guidelines.
S
6 termsSequence
The ordered arrangement of amino acid residues in a peptide chain, written by convention from the N-terminus to the C-terminus using standard three-letter or one-letter amino acid codes. The sequence determines the primary structure of a peptide and is the fundamental determinant of its receptor binding properties, biological activity and physicochemical characteristics. Sequence verification is performed analytically using mass spectrometry and Edman degradation.
Signal Transduction
The process by which a receptor-ligand interaction at the cell surface initiates a cascade of intracellular biochemical events leading to a cellular response. Signal transduction pathways are studied extensively in in vitro peptide pharmacology research using techniques including Western blotting, reporter gene assays, calcium imaging and phosphoproteomics. Common pathways investigated in peptide research include Gs-cAMP-PKA, Gq-PLC-IP3-calcium, PI3K-Akt-mTOR and MAPK-ERK cascades.
SKU
Stock Keeping Unit. A unique alphanumeric identifier assigned to each product variant in an inventory system. In the context of peptide research compounds, SKUs distinguish between different compounds, vial sizes, quantities and formulations within a product catalogue. SKUs are used for inventory management, order tracking and product identification.
Solid-Phase Peptide Synthesis
A chemical synthesis method in which a peptide chain is assembled stepwise on an insoluble resin support, one amino acid at a time, from the C-terminus to the N-terminus. SPPS, first developed by Robert Bruce Merrifield in 1963, is the standard manufacturing method for synthetic research peptides. Each coupling cycle involves deprotection, activation and coupling steps, followed by cleavage from the resin and purification by HPLC. SPPS enables the incorporation of non-standard amino acids, D-amino acids and chemical modifications at defined positions.
Structure-Activity Relationship (SAR)
The relationship between a compound's chemical structure and its observed biological activity at a target receptor or within a biological pathway. SAR studies systematically investigate how modifications to amino acid sequence, terminus chemistry, stereochemistry, cyclisation or conjugation influence receptor binding affinity, selectivity and downstream signalling. SAR research is fundamental to peptide analogue design and is conducted through iterative synthesis and pharmacological testing of structural variants.
Subcutaneous (SC)
A route of compound administration into the tissue layer between the skin and underlying muscle, studied as a pharmacokinetic research variable in preclinical in vivo models. Subcutaneous administration is investigated for its influence on absorption kinetics, depot formation and bioavailability. The subcutaneous space provides a depot site from which compounds are absorbed into systemic circulation at rates influenced by molecular weight, formulation and local tissue perfusion. SC pharmacokinetics are characterised in rodent and other preclinical research models.
T
2 termsTachyphylaxis
A rapid decrease in the biological response to a compound following repeated or continuous exposure. In preclinical peptide research, tachyphylaxis is studied as a pharmacological phenomenon related to receptor desensitisation, internalisation or downstream pathway attenuation. Tachyphylaxis is a significant variable in preclinical study design, particularly in secretagogue research where intermittent dosing protocols are investigated to characterise the relationship between receptor occupancy patterns and sustained signalling output.
Terminus Modification
A chemical modification applied to the N-terminus or C-terminus of a synthetic peptide. Common N-terminal modifications include acetylation and lipidation (such as palmitoylation). Common C-terminal modifications include amidation. Terminus modifications are investigated in preclinical research for their influence on metabolic stability, receptor binding and pharmacokinetic parameters. Capping both termini protects against exopeptidase degradation.
U
1 termsUPLC
Ultra-Performance Liquid Chromatography, also referred to as MS-UPLC when coupled with mass spectrometry detection. An advanced form of liquid chromatography that operates at higher pressures and uses smaller particle-size columns than conventional HPLC, providing faster separation, greater resolution and increased sensitivity. UPLC and MS-UPLC are used in peptide research for high-resolution purity analysis, impurity identification and compound verification. UPLC data complements HPLC analysis in Certificates of Analysis.
V
1 termsVial
A small sealed container used for the storage and dispensing of lyophilised peptide research compounds. Research peptide vials are typically made of borosilicate glass and are vacuum sealed to exclude moisture and atmospheric contaminants. Vials are stored in temperature-controlled, monitored cold storage systems to preserve compound integrity. Each vial is associated with a specific batch number and corresponding Certificate of Analysis.
Ready to explore our compounds?
Browse our full catalogue of research-grade peptides, all HPLC verified with third-party COA.
Browse Compounds